Category Archives: "News"

Mylan brings critical access to the multiple sclerosis community
HERTFORDSHIRE, England, and PITTSBURGH– August 19, 2020 – Mylan N.V. (NASDAQ: MYL) today announced the launch of the first [...]
WHO and AMA statement
"The Trump administration's official withdrawal from the World Health Organization (WHO) puts the health of our country at grave risk. As [...]
A letter from Lemtrada regarding its home phlebotomy partner, EMSI
Good Day Lemtrada Patient – On July 3, 2020 Sanofi Genzyme was notified that our Lemtrada Home Phlebotomy Partner, Examination [...]
Inebilizumab approved for treatment of Neuromyelitis Optica Spectrum Disorder
The US FDA has approved inebilizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 [...]
A position statement in 2020: a year of turmoil
Dear Members of the Consortium of Multiple Sclerosis Centers (CMSC): The leadership of the Board of Governors of the CMSC has crafted [...]
In memoriam Susan E. Bennett, PT, DPT, EdD, NCS, MSCS
Sue Bennett with June Halper POSTPONEMENT   Due to continued concerns regarding COVID, only a limited amount of people are able to [...]
Multiple sclerosis patients can benefit from expanded services from MSAA
In light of the COVID-19 pandemic and its impact on the MS community, please know the Multiple Sclerosis Association of American (MSAA) has [...]
ZEPOSIA launch press release
Bristol Myers Squibb Announces Commercial Launch and Availability of ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of [...]
Rebif® U.S. label includes pregnancy outcomes & lactation information
- Label update is based on data from a large register-based study, as well as other published studies over several decades - Multiple [...]
New 6-year data for Genentech’s Ocrevus (ocrelizumab) findings
New 6-Year Data for Genentech’s Ocrevus (ocrelizumab) Show Earlier Treatment Initiation Nearly Halves Risk of Needing Walking Aid in [...]

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us
I have a question about
First
Last

Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM